PolTREG at 5th Treg Summit in Boston!
See other news
PolTREG appoints Dan Shelly, PhD, MBA as Chief Business Development Officer to help it build partnerships across industry and deliver milestones
Global institutional investors and investment funds hold over 25% of PolTREG’s shares.
Prof. Piotr Trzonkowski co-authors peer-reviewed article showing scientific progress in T-regautoimmune therapy
PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes
The J.P. Morgan Healthcare Conference 2024 is already behind us!
PolTREG at J.P. Morgan Healthcare Conference
PolTREG completes next stage of state-of-the-art manufacturing facility
“The promises of Treg autoimmune therapy – all in one hand” – PolTREG publishes new investor slide deck